Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Manuel Nogarotto"'
Autor:
Estevão Carlos Silva Barcelos, Chiara Rompietti, Francesco Maria Adamo, Erica Dorillo, Filomena De Falco, Beatrice Del Papa, Stefano Baldoni, Manuel Nogarotto, Angela Esposito, Silvia Capoccia, Clelia Geraci, Daniele Sorcini, Arianna Stella, Roberta Arcaleni, Valentina Tini, Flávia Imbroisi Valle Errera, Emanuela Rosati, Paolo Sportoletti
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionConstitutive activation of NOTCH1-wild-type (NT1-WT) signaling is associated with poor outcomes in chronic lymphocytic leukemia (CLL), and NOTCH1 mutation (c.7541_7542delCT), which potentiates NOTCH1 signaling, worsens the prognosis. Howe
Externí odkaz:
https://doaj.org/article/42a87a28abc246f28270a9eea157bbfb
Autor:
Stefano Baldoni, Beatrice Del Papa, Filomena De Falco, Erica Dorillo, Carlo Sorrentino, Chiara Rompietti, Francesco Maria Adamo, Manuel Nogarotto, Debora Cecchini, Elena Mondani, Estevao Carlos Silva Barcelos, Lorenzo Moretti, Maria Grazia Mameli, Bianca Fabi, Daniele Sorcini, Arianna Stella, Raffaella Giancola, Francesco Guardalupi, Francesca Ulbar, Sara Plebani, Valerio Guarente, Emanuela Rosati, Marta Di Nicola, Michele Marchioni, Mauro Di Ianni, Paolo Sportoletti
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
NOTCH1 mutations and deregulated signal have been commonly found in chronic lymphocytic leukemia (CLL) patients. Whereas the impact of NOTCH1 mutations on clinical course of CLL has been widely studied, the prognostic role of NOTCH1 activation in CLL
Externí odkaz:
https://doaj.org/article/bf604ad42c61485b9c589e15303f6899
Autor:
Paolo Sportoletti, Emanuela Rosati, Mauro Di Ianni, Franca Falzetti, Maria Paola Martelli, Guido Montanaro, Andrea Marra, Ambra Di Tommaso, Roberta Iacucci Ostini, Elisa Albi, Estevão Carlos Silva Barcelos, Federica Mezzasoma, Francesco Maria Adamo, Manuel Nogarotto, Daniele Sorcini, Maria Grazia Cantelmi, Debora Cecchini, Chiara Rompietti, Filomena De Falco, Erica Dorillo, Stefano Baldoni, Beatrice Del Papa
Figure S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bec17ba17c9787a614b9bbd2801f41c
https://doi.org/10.1158/1078-0432.22471380
https://doi.org/10.1158/1078-0432.22471380
Autor:
Paolo Sportoletti, Emanuela Rosati, Mauro Di Ianni, Franca Falzetti, Maria Paola Martelli, Guido Montanaro, Andrea Marra, Ambra Di Tommaso, Roberta Iacucci Ostini, Elisa Albi, Estevão Carlos Silva Barcelos, Federica Mezzasoma, Francesco Maria Adamo, Manuel Nogarotto, Daniele Sorcini, Maria Grazia Cantelmi, Debora Cecchini, Chiara Rompietti, Filomena De Falco, Erica Dorillo, Stefano Baldoni, Beatrice Del Papa
Supplementary Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08213d6c0f6644f20568831b0e789e00
https://doi.org/10.1158/1078-0432.22471362.v1
https://doi.org/10.1158/1078-0432.22471362.v1
Autor:
Paolo Sportoletti, Emanuela Rosati, Mauro Di Ianni, Franca Falzetti, Maria Paola Martelli, Guido Montanaro, Andrea Marra, Ambra Di Tommaso, Roberta Iacucci Ostini, Elisa Albi, Estevão Carlos Silva Barcelos, Federica Mezzasoma, Francesco Maria Adamo, Manuel Nogarotto, Daniele Sorcini, Maria Grazia Cantelmi, Debora Cecchini, Chiara Rompietti, Filomena De Falco, Erica Dorillo, Stefano Baldoni, Beatrice Del Papa
Purpose:Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), has improved the outcomes of chronic lymphocytic leukemia (CLL), but primary resistance or relapse are issues of increasing significance. While the predominant mechanism of action of BTKi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ff165291a87757c7b419c2e16d63a2
https://doi.org/10.1158/1078-0432.c.6527862
https://doi.org/10.1158/1078-0432.c.6527862
Autor:
Paolo Sportoletti, Emanuela Rosati, Mauro Di Ianni, Franca Falzetti, Maria Paola Martelli, Guido Montanaro, Andrea Marra, Ambra Di Tommaso, Roberta Iacucci Ostini, Elisa Albi, Estevão Carlos Silva Barcelos, Federica Mezzasoma, Francesco Maria Adamo, Manuel Nogarotto, Daniele Sorcini, Maria Grazia Cantelmi, Debora Cecchini, Chiara Rompietti, Filomena De Falco, Erica Dorillo, Stefano Baldoni, Beatrice Del Papa
Tables S1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b72ae2fb7c88075d972832722c2a1c
https://doi.org/10.1158/1078-0432.22471359.v1
https://doi.org/10.1158/1078-0432.22471359.v1
Autor:
Daniele Sorcini, Manuel Nogarotto, Beatrice Del Papa, Paolo Sportoletti, Erica Dorillo, Mauro Di Ianni, Emanuela Rosati, Francesco Maria Adamo, Filomena De Falco, Maria Paola Martelli, Stefano Baldoni, Elisa Albi, Federica Mezzasoma, Roberta Iacucci Ostini, Chiara Rompietti, Franca Falzetti, Andrea Marra, Maria Grazia Cantelmi, Ambra Di Tommaso, Debora Cecchini, Estevão Carlos Silva Barcelos, Guido Montanaro
Publikováno v:
Clinical Cancer Research. 25:7540-7553
Purpose: Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), has improved the outcomes of chronic lymphocytic leukemia (CLL), but primary resistance or relapse are issues of increasing significance. While the predominant mechanism of action of BTKi